Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
Kawakami H, Sunakawa Y, Inoue E, Matoba R, Noda K, Sato T, Suminaka C, Yamaki M, Sakamoto Y, Kawabata R, Ishiguro A, Akamaru Y, Kito Y, Yabusaki H, Matsuyama J, Takahashi M, Makiyama A, Hayashi H, Chamoto K, Honjo T, Nakagawa K, Ichikawa W, Fujii M. Kawakami H, et al. Among authors: akamaru y. Eur J Cancer. 2023 May;184:10-20. doi: 10.1016/j.ejca.2023.02.003. Epub 2023 Feb 10. Eur J Cancer. 2023. PMID: 36889037
Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T. Nishikawa K, et al. Among authors: akamaru y. Eur J Cancer. 2015 May;51(7):808-16. doi: 10.1016/j.ejca.2015.02.009. Epub 2015 Mar 18. Eur J Cancer. 2015. PMID: 25797356 Free article. Clinical Trial.
Effects of an Oral Elemental Nutritional Supplement on Post-gastrectomy Body Weight Loss in Gastric Cancer Patients: A Randomized Controlled Clinical Trial.
Imamura H, Nishikawa K, Kishi K, Inoue K, Matsuyama J, Akamaru Y, Kimura Y, Tamura S, Kawabata R, Kawada J, Fujiwara Y, Kawase T, Fukui J, Takagi M, Takeno A, Shimokawa T. Imamura H, et al. Among authors: akamaru y. Ann Surg Oncol. 2016 Sep;23(9):2928-35. doi: 10.1245/s10434-016-5221-4. Epub 2016 Apr 15. Ann Surg Oncol. 2016. PMID: 27084538 Clinical Trial.
Long-term effects of an oral elemental nutritional supplement on post-gastrectomy body weight loss in gastric cancer patients (KSES002).
Kimura Y, Nishikawa K, Kishi K, Inoue K, Matsuyama J, Akamaru Y, Tamura S, Kawada J, Kawase T, Kawabata R, Fujiwara Y, Kanno H, Yamada T, Shimokawa T, Imamura H. Kimura Y, et al. Among authors: akamaru y. Ann Gastroenterol Surg. 2019 Oct 10;3(6):648-656. doi: 10.1002/ags3.12290. eCollection 2019 Nov. Ann Gastroenterol Surg. 2019. PMID: 31788653 Free PMC article.
A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601).
Terazawa T, Matsuyama J, Goto M, Kawabata R, Endo S, Imano M, Fujita S, Akamaru Y, Taniguchi H, Tatsumi M, Lee SW, Kurisu Y, Kawakami H, Kurokawa Y, Shimokawa T, Sakai D, Kato T, Fujitani K, Satoh T. Terazawa T, et al. Among authors: akamaru y. Oncologist. 2020 Feb;25(2):119-e208. doi: 10.1634/theoncologist.2019-0601. Epub 2019 Sep 30. Oncologist. 2020. PMID: 32043772 Free PMC article. Clinical Trial.
Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: Exploratory analysis of the randomized phase III TRICS trial.
Nishikawa K, Murotani K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Hasegawa H, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T. Nishikawa K, et al. Among authors: akamaru y. Eur J Cancer. 2020 Jun;132:159-167. doi: 10.1016/j.ejca.2020.03.027. Epub 2020 May 5. Eur J Cancer. 2020. PMID: 32380427 Clinical Trial.
Comparison of S-1-cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.
Kawakami H, Fujitani K, Matsuyama J, Akamaru Y, Tamura S, Endo S, Kimura Y, Makari Y, Tamura T, Sugimoto N, Sakai D, Tsujinaka T, Goto M, Kurokawa Y, Shimokawa T, Satoh T; Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG). Kawakami H, et al. Among authors: akamaru y. Int J Clin Oncol. 2020 Sep;25(9):1635-1643. doi: 10.1007/s10147-020-01711-z. Epub 2020 Jun 3. Int J Clin Oncol. 2020. PMID: 32494981 Clinical Trial.
Multicenter prospective trial of total gastrectomy versus proximal gastrectomy for upper third cT1 gastric cancer.
Yamasaki M, Takiguchi S, Omori T, Hirao M, Imamura H, Fujitani K, Tamura S, Akamaru Y, Kishi K, Fujita J, Hirao T, Demura K, Matsuyama J, Takeno A, Ebisui C, Takachi K, Takayama O, Fukunaga H, Okada K, Adachi S, Fukuda S, Matsuura N, Saito T, Takahashi T, Kurokawa Y, Yano M, Eguchi H, Doki Y. Yamasaki M, et al. Among authors: akamaru y. Gastric Cancer. 2021 Mar;24(2):535-543. doi: 10.1007/s10120-020-01129-6. Epub 2020 Oct 29. Gastric Cancer. 2021. PMID: 33118118 Clinical Trial.
Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08).
Takahashi Y, Sunakawa Y, Inoue E, Kawabata R, Ishiguro A, Kito Y, Akamaru Y, Takahashi M, Yabusaki H, Matsuyama J, Makiyama A, Tsuda M, Suzuki T, Yasui H, Matoba R, Kawakami H, Nakajima TE, Muro K, Ichikawa W, Fujii M. Takahashi Y, et al. Among authors: akamaru y. Gastric Cancer. 2022 Jan;25(1):235-244. doi: 10.1007/s10120-021-01237-x. Epub 2021 Aug 24. Gastric Cancer. 2022. PMID: 34427838
81 results